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Objective: To estimate the prevalence of unidentified chronic ob-
structive pulmonary disease (COPD) and determine the screening 
accuracy of the Lung Function Questionnaire (LFQ).
Patients and MethOds: Cigarette smokers who had a smoking 
history of 10 or more pack-years and were aged 30 years or older 
were recruited from 36 centers from February 18, 2009, to May 
29, 2009. A total of 1575 patients completed a Web-based survey 
including the 5-item LFQ. Spirometry was performed on patients 
with an LFQ total score of 18 or less and on a subset scoring more 
than 18. The primary outcome was the proportion of patients at 
risk of airflow obstruction as measured by the LFQ (score, ≤18) in 
whom an airflow obstruction was confirmed by spirometry.
Results: Of the patients who completed the LFQ, 849 (54%) had 
standardized spirometry data available. On the basis of LFQ and 
spirometry results, the estimated prevalence of possible COPD 
was 17.9% (95% confidence interval, 15.3%-20.6%). At a cut point 
of 18 or less, sensitivity, specificity, positive predictive value, and 
negative predictive value of the LFQ were 88%, 25%, 21%, and 
90%, respectively. Approximately 1 in 5 patients (21%) aged 30 
years or older and 1 in 4 (26%) aged 50 years or older scored 18 or 
less on the LFQ and had a ratio of forced expiratory volume in the 
first second of expiration to forced vital capacity less than 0.70.
cOnclusiOn: On the basis of postbronchodilator spirometry 
results using weighted estimates, approximately 1 in 5 patients 
(21%) aged 30 years or older with a smoking history of 10 or more 
pack-years seen in a primary care setting is likely to have COPD. 
The LFQ could be a helpful COPD case-finding tool for clinicians to 
identify patients who need further evaluation. 
Trial Registration: clinicaltrials.gov identifier: nct01013948
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COPD = chronic obstructive pulmonary disease; FEV1 = forced expira-
tory volume in the first second of expiration; FVC = forced vital capac-
ity; LFQ = Lung Function Questionnaire
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Chronic obstructive pulmonary disease (COPD) is cur-rently the third leading cause of death in the United 
States,1 and the number of deaths is increasing, especially 
among women.2 Currently, more than 12 million people in 
the United States are diagnosed as having COPD, but the true 
prevalence is estimated to be more than double this number.3,4 
The Third National Health and Nutrition Examination Survey 
(NHANES) examined more than 14,000 adults from across 
the United States with a battery of tests that included spirom-
etry and respiratory symptom questionnaires and found that 
COPD was undiagnosed in almost two-thirds of individuals 
with airflow obstruction.5,6 In the NHANES, most of those 
with undiagnosed obstruction reported having chronic respi-
ratory symptoms and COPD-related physical impairment that 
negatively affected their day-to-day lives.7 Although clini-
cal trials such as the Lung Health Study demonstrated that 
early diagnosis and aggressive interven-
tions in COPD can improve long-term 
outcomes,8-11 COPD is not diagnosed in 
most patients until they have long-stand-
ing symptoms, experience complications 
such as pneumonia, or develop other smoking-related condi-
tions such as cardiovascular disease or cancer.
 Screening programs for COPD have not gained wide-
spread acceptance.12-14 Demonstration of airflow obstruction 
with spirometry is considered the standard for confirming 
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the diagnosis of COPD but is a more physically challeng-
ing screening test than other screening tests, such as blood 
pressure or serum glucose screening. A recent US Preventive 
Services Task Force investigation did not support the routine 
use of spirometry for COPD screening.13,15 Among the rea-
sons cited for this decision were the large time commitment 
for both the patient and the health care system for success-
ful testing, lack of data suggesting a positive cost-benefit 
ratio, and a small but significant false-positive rate among 
healthy individuals. Spirometry is also not recommended as 
a screening tool among asymptomatic patients.16 Therefore, 
efficient screening tools for identifying persons at risk of un-
diagnosed COPD are still needed.17
 To address this issue, we developed the Lung Function 
Questionnaire (LFQ), a 5-item self-administered question-
naire intended for use in COPD screening programs and in 
primary care settings.18 In a previous publication, we de-
scribed the development and initial testing of the LFQ.18 
The objectives of this study were to estimate, within a pri-
mary care setting, the prevalence of unidentified COPD 
and to determine the screening accuracy of this simple, 
self-administered screening tool for COPD.
PATIENTS AND METhODS
This multicenter, noninterventional, cross-sectional study 
was conducted from February 18, 2009, to May 29, 2009, in 
the primary care setting and included patients with a history 
of cigarette smoking who were not taking medication for 
COPD or asthma. The primary objective of this study was 
to estimate the prevalence of chronic airway obstruction in 
patients in a primary care setting with a history of cigarette 
smoking (previous and current smokers) using the LFQ as a 
screening tool and spirometry for subsequent confirmation. 
Secondary objectives included examining psychometric 
properties of the LFQ overall as well as its performance in 
patients with abnormal spirometry results.
Site RecRuitment and Patient enRollment
The study was conducted at 36 primary care centers in 
the United States. Sites were recruited from 4 geographic 
regions (the Northeast, South, Midwest, and West) using 
a proprietary database of about 1400 physicians who had 
previously expressed interest in conducting research and 
were members of the Primary Care Network. The study 
was approved by a central institutional review board, and 
each patient provided written informed consent before 
study procedures.
 The study population included current or previous ciga-
rette smokers aged 30 years or older at screening who had a 
minimum smoking history of 10 pack-years. Patients were 
ineligible to participate if they reported any regular (ie, on 
a daily basis) use of respiratory medications in the 4 weeks 
before the study visit. A known diagnosis of substantial 
lung conditions was exclusionary. A previous diagnosis of 
an obstructive lung disease was not exclusionary if the pa-
tient met the criteria for medication use.
Study aSSeSSmentS
 Lung Function Questionnaire. Patients completed the 
LFQ, which consists of 5 questions scored on a 5-point 
scale, with lower scores indicating increased risk of air-
flow obstruction. On the basis of previous validation of the 
LFQ, a total score of 18 or less suggests an increased risk 
of airway obstruction. In addition to the LFQ, the patient 
questionnaire included questions about current medical 
history, smoking habits, resource utilization history, and 
demographics.
 Spirometry. All patients with a total LFQ score of 18 
or less, and the first 2 patients completing the question-
naire who scored more than 18 at each site, were selected 
for prebronchodilator and postbronchodilator spirometry, 
performed by trained site staff. After an initial prebroncho-
dilator maneuver, each patient selected for spirometry self-
administered 4 puffs (360 µg) of albuterol via metered-dose 
inhaler for the spirometric determination of postbronchodi-
lator ratio of forced expiratory volume in the first second of 
expiration (FEV
1
) to forced vital capacity (FVC); a ratio less 
than 0.70 was considered to demonstrate airway obstruction 
characteristic of the disease.19 Spirometry was conducted us-
ing standardized equipment (Biomedical Systems, St Louis, 
MO) that meets or exceeds the minimum performance rec-
ommendations of the American Thoracic Society.20 Only 
data collected from acceptable spirometric maneuvers were 
included in the analysis. If spirometric maneuvers were un-
acceptable, patients were allowed to repeat this procedure 
within 7 days of completion of the study visit; those who did 
not return were withdrawn from the study.
StatiStical methodS
Data from all patients who completed all questions on the 
LFQ were included in the analysis. The estimated preva-
lence of COPD was based on LFQ and spirometry results. 
Patients who scored 18 or less were classified as having 
an airflow obstruction if the postbronchodilator FEV
1
/FVC 
ratio was less than 0.70.
 To minimize potential selection bias, weighted estimates 
of prevalence were calculated by taking the weighted mean 
of the prevalence estimates within each of the 4 geograph-
ic regions. The region weight was defined as the propor-
tion of people residing in each specified region who would 
qualify to participate in the study compared with the total 
number of people in the United States who would qualify 
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to participate in the study. Other ad hoc analyses were un-
dertaken to further understand LFQ results among patients 
not classified as having an airflow obstruction. These in-
cluded outcomes for both prebronchodilator and postbron-
chodilator spirometry values and distributions on the basis 
of the age and smoking history of patients who were at 
risk according to the LFQ and were confirmed as such 
by prebronchodilator or postbronchodilator spirometry. 
 Estimates of screening accuracy (ie, sensitivity, specific-
ity, positive predictive value, negative predictive value, and 
percentage correctly classified) were computed using the 
methods described by Begg and Greenes.21 Positive predic-
tive value was defined as [Number of Patients With LFQ 
score <18 and FEV
1
/FVC <0.70] / [Number of Patients With 
LFQ score <18]. Similarly, negative predictive value was de-
fined as [Number of Patients With LFQ Score >18 and FEV
1
/
FVC ≥0.70] / [Number of Patients With LFQ score >18].
 The LFQ was designed as a case-finding tool rather 
than an instrument measuring a single health-status con-
cept; consequently, a high level of internal consistency was 
not anticipated. By design, the items serve as indicators of 
disparate factors that, taken together, predict the likelihood 
of obstruction. For the proportion of patients who scored 
18 or less on the LFQ without completing spirometry satis-
factorily according to the American Thoracic Society/Eu-
ropean Respiratory Society criteria, weighted estimates of 
regional prevalence were derived.
RESuLTS
Study SamPle
Of 4956 patients with a smoking history who were invited, 
2284 current or former smokers (46%) completed the case-
finding questionnaire. Of these 2284 patients, 1724 (75%) 
were eligible according to study criteria. Completed LFQs 
were obtained from 1575 patients (69%) during the study 
visit. On the LFQ,  1216 patients (77%) scored 18 or less, 
and 359 patients (23%) scored more than 18.
 Of the 1288 patients eligible for spirometry, 849 (66%) 
completed a postbronchodilator spirometry session meeting 
American Thoracic Society/European Respiratory Society cri-
teria. The consort diagram for the study is shown in Figure 1.
demogRaPhicS and BaSeline chaRacteRiSticS
Demographic characteristics and general health informa-
tion are shown in Table 1. These results are grouped by 
560 Ineligible
149 Never returned for study visit
287 Not selected for spirometry
27 Spirometry not performed per protocol
349 Spirometry did not meet ATS/ERS criteria
4956 Adult patients aged ≥30 years with a smoking history
2672 Not screened2284 Screened
1724 Eligible
1575 Enrolled and completed LFQ
           359 LFQ >18
         1216 LFQ ≤18
56 Refused spirometry
7 Ineligible
1288 Selected for spirometry
             73 LFQ >18
         1215 LFQ ≤18
1225 Spirometry attempted
             70 LFQ >18
         1155 LFQ ≤18
849 Acceptable spirometry
         49 LFQ >18
       800 LFQ ≤18
FiGuRe 1. consort diagram of disposition of patients in study. ats = american thoracic society; eRs = european Respiratory 
society; lFQ = lung Function Questionnaire.
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LFQ cut-point score (LFQ ≤18, 1216 patients; LFQ >18, 
359 patients) and for the subsample who completed spirom-
etry (LFQ ≤18 and spirometry, 800 patients; LFQ >18 and 
spirometry, 49 patients).
 In general, the demographics were similar across 
groups, with a few exceptions. The group with an LFQ 
score of more than 18 had a slightly different ethnic dis-
tribution (fewer non-Hispanic white patients) and a larger 
percentage of patients from the West than the group with 
an LFQ score of 18 or less. In addition, patients with an 
LFQ score of more than 18 who completed spirometry 
were less likely to have a body mass index greater than 30 
(calculated as the weight in kilograms divided by height 
in meters squared). Finally, on average, patients with 
an LFQ score of more than 18 reported fewer comorbid 
conditions and fewer pack-years than patients with lower 
LFQ scores, independent of whether they had completed 
spirometry.
PRevalence of aiRway oBStRuction
On the basis of LFQ and spirometry results, the weighted 
estimate of prevalence of not fully reversible airflow ob-
struction (defined as LFQ score ≤18 and confirmed by a 
postbronchodilator FEV
1
/FVC ratio <0.70) in current or 
former smokers seen in primary care is 17.9% (95% con-
fidence interval, 15.3%-20.6%). Approximately 1 in 5 
patients (21%) aged 30 years or older and 1 in 4 patients 
(26%) aged 50 years or older scored 18 or less on the LFQ 
and had an FEV
1
/FVC ratio less than 0.70 (Table 2).
 When age was considered in combination with smok-
ing (measured by pack-years), the trend of patients with ob-
struction identified by the LFQ and confirmed by spirom-
etry moved in an expected direction (Table 2). For instance, 
of patients aged 50 years or older who had a smoking his-
tory of 30 pack-years or more, 1 in 3 scoring 18 or less on 
the LFQ was confirmed to have an obstruction.
 We also examined patients who had abnormal spirom-
etry results (FEV
1
 <80% of predicted, both prebroncho-
dilator and postbronchodilator) and restricted spirom-
etry results (FEV
1
/FVC ratio ≥0.70 but FEV
1
 <80%, all 
postbronchodilator).
 Of the 191 patients who had an FEV
1
/FVC ratio of 0.70 
or more and whose FEV
1
 was less than 80% of predicted, 
182 (95%) scored 18 or less on the LFQ, thus underscoring 
the usefulness of the LFQ as a case-finding tool. This group 
had an average smoking history of 36.5 pack-years, mean 
body mass index of 31, and mean age of 54 years. The de-
mographic characteristics of this patient population reflect 
those of the larger study population.
evaluation of the lfQ
Patients who completed spirometry (n=849) included 800 
(94%) selected because they scored 18 or less on the LFQ. 
The cut point of 18 was suggested by earlier studies to be 
the most predictive of patients who should be evaluated 
with spirometry for possible obstruction.18,22 In these 849 
patients, 175 postbronchodilator spirometry tests (21%) 
resulted in an FEV
1
/FVC ratio of less than 0.70, indicating 
table 1. Patient Demographic Characteristics by LFQ Cut Point and for Sample Completing Spirometrya
 
   LFQ ≤18 and  LFQ >18 and
 LFQ ≤18  LFQ >18  completed spirometry  completed spirometry
 (n=1216) (n=359) (n=800) (n=49)
Age (y) 55.0±11.8 50.0±11.8 54.6±11.5 45.1±10.7
Male 620 (51.0) 187 (52.1) 402 (50.3) 28 (57.1)
Race/ethnicity    
 Non-Hispanic white 908 (74.7) 202 (56.3) 618 (77.3) 33 (67.3)
 Non-Hispanic African American 113 (9.3) 36 (10.0) 61 (7.6) 2 (4.1)
 Non-Hispanic other 60 (4.9) 44 (12.3) 39 (4.9) 5 (10.2)
 Hispanic 71 (5.8) 57 (15.9) 42 (5.3) 4 (8.2)
 Unspecified 64 (5.3) 20 (5.6) 40 (5.0) 5 (10.2)
Region    
 Northeast 146 (12.0) 20 (5.6) 72 (9.0) 2 (4.1)
 Midwest 204 (16.8) 59 (16.4) 127 (15.9) 8 (16.3)
 South 641 (52.7) 86 (24.0) 456 (57.0) 29 (59.2)
 West 225 (18.5) 194 (54.0) 145 (18.1) 10 (20.4)
BMIb 29.8±6.6 28.9±6.3 29.9±6.7 26.9±4.3
BMI >30 498 (41.0) 129 (35.9) 332 (41.5) 14 (28.6)
No. of comorbid conditions 4.0±3.4 2.8±2.6 4.0±3.3 2.4 ±2.6
No history of comorbid conditions 161 (13.2) 74 (20.6) 93 (11.6) 18 (36.7)
Smoking status    
 Current smoker 748 (61.5) 159 (44.3) 475 (59.4) 26 (53.1)
No. of pack-years 34.3±21.9 21.8±11.5 34.2±21.7 20.6±8.9
a Categorical values are provided as number (percentage) of patients and continuous values as mean ± SD unless specified otherwise. BMI = body 
mass index; LFQ = Lung Function Questionnaire.
b Calculated as the weight in kilograms divided by height in meters squared.
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table 2. Proportion of Patients Scoring ≤18 on the LFQ in 
Whom Obstruction Was Confirmed by 
Prebronchodilator or Postbronchodilator Spirometrya,b
 Smoking history (pack-years)
 >10 >20 >30 >40
Prebronchodilator
 Age (y)
  ≥30 237/800 203/610 163/410 113/243 
   (30)  (33)  (40)  (47)
  ≥40 223/713 199/572 162/399 113/238 
   (31)  (35)  (41)  (47)
  ≥50 196/532 176/439 147/322 107/210 
   (37)  (40)  (46)  (51)
Postbronchodilator
 Age (y)
  ≥30 170/800 146/610 118/410 81/243 
   (21)  (24)  (29) (33)
  ≥40 162/713  144/572  118/399  81/238
   (23) (25) (30) (34)
  ≥50 136/532  121/439  102/322  75/210
   (26) (28) (32) (36)
a Obstruction is defined as the ratio of forced expiratory volume in the 
first second of expiration to forced vital capacity less than 0.70. 
b Data are provided as number (percentage) of patients. The denominator 
indicates the number of patients in each category who scored ≤18 on the 
Lung Function Questionnaire (LFQ) and were “at risk” of obstruction. 
The numerator denotes the number of these patients in whom obstruction 
was confirmed using prebronchodilator or postbronchodilator spirometry.
obstruction, and 674 (79%) resulted in an FEV
1
/FVC ratio 
of 0.70 or more, indicating no obstruction.
 Of the 800 patients with an LFQ score of 18 or less, 
170 (21%) had confirmed obstruction on the basis of their 
FEV
1
/FVC ratio of less than 0.70. Figure 2 provides a 
graphic display of the total LFQ score frequency for all 
patients in the study sample, as well as the frequency for 
patients who successfully completed spirometry (n=849). 
Most patients who completed spirometry had an LFQ score 
between 13 and 19.
 On the basis of the current cut point (≤18), the LFQ has 
a sensitivity of 88% and a specificity of 25%. At a score 
of 18 in patients aged 30 years or older, 21% of those who 
were screened as possibly having an airflow obstruction 
on the basis of the LFQ were confirmed by spirometry to 
have one (positive predictive value), and 90% of those who 
were screened as not having an airflow obstruction by the 
LFQ were confirmed by spirometry not to have one (nega-
tive predictive value). Overall, 37% of the patients were 
correctly classified as having airflow obstruction on the 
basis of postbronchodilator spirometry results at this LFQ 
cut point. Of patients who were not taking any respiratory 
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FiGuRe 2. Frequency of total score on lung Function Questionnaire (lFQ) for patient population with successful spirom-
etry and the subset confirmed to have airway obstruction.
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had an FEV
1
/FVC ratio of less than 0.70, 762 (95%) did 
not report a previous diagnosis of COPD.
DISCuSSION
This study sought to determine the prevalence of airway 
obstruction in smokers in a primary care setting using the 
LFQ as a case-finding tool and confirming the diagnosis 
with spirometry. Previous epidemiological studies of COPD 
prevalence either have been non–clinic-based4 or have used 
ambulatory care claims data. This cross-sectional survey of 
ambulatory clinics is representative of what primary care 
physicians are likely to see in their offices.
 In the primary care offices studied, obstructive airway 
disease was not uncommon in any age group screened, even 
in those younger than 50 years, who are rarely assessed for 
COPD in primary care. The LFQ retained high sensitivity 
and negative predictive value, important characteristics for 
case-finding purposes.
 A simple, cost-effective strategy to identify a large 
group of patients with undiagnosed symptomatic ob-
structive lung disease is needed to address this important 
public health concern. Most primary care physicians do 
not have office spirometry equipment and thus do not 
have ready access to an objective test necessary for both 
diagnosis and management of COPD. The LFQ may be 
adopted as a method to identify patients at risk of ob-
structive lung disease. An LFQ score of 18 or less might 
encourage primary care physicians to refer patients for 
spirometry. Given its high negative predictive value, the 
LFQ also has the potential to decrease the use of spirom-
etry in asymptomatic patients and guide other diagnos-
tic evaluations in symptomatic patients with spirometric 
evidence of obstructive lung disease.22,23
 Although our primary aim in the development of the 
LFQ was to identify patients who were candidates for fur-
ther assessment using spirometry (and potentially to iden-
tify undiagnosed cases of COPD), a substantial number of 
abnormal spirometry measures (eg, FEV
1
 <80% of pre-
dicted) were also identified using the LFQ. We based our 
a priori criteria for the success of the LFQ on its ability to 
detect airway obstruction, but its clinical utility may actu-
ally be much greater because of its potential also to detect 
clinically important restrictive diseases.
 The National Lung Health Education Program previ-
ously recommended screening spirometry for all current or 
former smokers aged 40 years or older to identify undi-
agnosed COPD.24 However, on the basis of the results of 
the Agency for Heathcare Research and Quality evidence 
report and the recommendations of the US Preventive Ser-
vices Task Force, most organizations no longer recommend 
this approach of universal screening.23 We found that 762 
(95%) of 800 patients recruited from a primary care set-
ting who were not taking any respiratory medications, who 
scored 18 or less on the LFQ, and who had an FEV
1
/FVC 
ratio of less than 0.70 did not report a previous diagnosis of 
COPD. Thus, the LFQ, as a preliminary case-finding tool, 
may be an acceptable alternative to mass screening.
 The estimated COPD prevalence of 17.9% in primary 
care practice is much higher than the 3.0% to 5.0% preva-
lence in the general population.6 This finding may not be 
entirely unexpected because people visiting primary care 
physicians are a population generally more inclined to seek 
care for signs, symptoms, and previously recognized dis-
eases. The practice-based prevalence will of course vary by 
age and smoking prevalence in this population.
 This study has limitations. Selection bias is a potential 
limitation that could lead to an overestimation or underes-
timation of prevalence if outcomes of interest are signifi-
cantly different in study patients vs the general population. 
To limit selection bias at the initial recruitment stage, sites 
were trained to use standardized recruitment protocols to 
screen and recruit eligible patients. Further, spirometry 
was performed only on a subset of patients. It should also 
be noted that the assessment of screening accuracy in the 
current study was limited because only a small subset scor-
ing more than 18 on the LFQ completed spirometry. This 
study population may not be representative of the entire 
primary care population.
CONCLuSION
Case finding using the LFQ identified an estimated 18% 
prevalence of obstructive lung disease in patients aged 30 
years or older visiting primary care practices in this study. 
The LFQ can be self-administered or administered by phy-
sicians' office staff in the waiting room, potentially saving 
time that can be used for follow-up questions and symptom 
identification. It could prove useful and acceptable in the 
identification of patients who are candidates for spirometric 
evaluation.
The authors acknowledge Andrea Morris, BSN, employed by 
GlaxoSmithKline, for editorial assistance and critical review dur-
ing the development of the submitted manuscript.
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